Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A de Jonge

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
Public Health|July 21, 2024
Effect of COVID-19 lockdown on maternity care and maternal outcome in the Netherlands: a national quasi-experimental studyB Y Gravesteijn, N W Boderie, T van den Akker, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
The Oncologist|September 25, 2016
Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue BiopsiesSander Bins, Geert A Cirkel, Christa G Gadellaa-Van Hooijdonk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery ProtocolBirgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, et al.
Blood Neoplasia|June 2, 2025
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in BelgiumPaul G Kemps, F J Sherida H Woei-A-Jin, Patrick Schöffski, et al.
Circulation. Genomic and Precision Medicine|April 10, 2026
Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid CancerFrits I Mulder, Noori A M Guman, Job van Riet, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Public Health|July 21, 2024
Effect of COVID-19 lockdown on maternity care and maternal outcome in the Netherlands: a national quasi-experimental studyB Y Gravesteijn, N W Boderie, T van den Akker, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
The Oncologist|September 25, 2016
Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue BiopsiesSander Bins, Geert A Cirkel, Christa G Gadellaa-Van Hooijdonk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery ProtocolBirgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, et al.
Blood Neoplasia|June 2, 2025
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in BelgiumPaul G Kemps, F J Sherida H Woei-A-Jin, Patrick Schöffski, et al.
Circulation. Genomic and Precision Medicine|April 10, 2026
Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid CancerFrits I Mulder, Noori A M Guman, Job van Riet, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.
Pageof 23